Overview
Singhe Hospitals is a Sri Lankan hospital and nursing-management business. The latest comparable March quarter shows a sharp improvement in operating execution: its operating margin ranked best among the company's comparable March quarters, although gross margin ranked worst. This creates a clear tension between stronger operating performance and a valuation that already prices in substantial progress.
Price performance
The share closed at LKR 21.10 on 2026-08-07. Over one year it gained 182.7%, far ahead of the ASPI's 9.5% gain, while the three-month return was a decline of 5.8% against a 7.1% fall for the index.
The stock sits at 78.5% of its 52-week range. Recent volatility is 5.6% below its own one-year level, while 20-day average volume is 30.5% below its 60-day average, indicating quieter trading activity despite the large longer-term price gain.
Valuation
The valuation is stretched against healthcare peers: the P/E of 41.95 compares with a sector median of 11.14, and the P/B of 7.56 compares with a sector median of 1.56. No sector percentile is supplied, but both multiples place the stock well above the available peer medians.
ROE is 4.7%, which provides limited fundamental support for such a high P/B. The stock has no dividend yield, and dividend history is not supplied, so there is no evidence of a growing or stable payout to offset the valuation premium.
News and sentiment
Direct coverage is thin: there were no material company articles in the 90-day window, with no positive, negative or neutral articles recorded. No confirmed or undated corporate actions are reported.
Financials
The latest quarter ended 2026-03-31 and reported gross margin of 56.5%, operating margin of 21.6% and net margin of 10.1%. The corresponding March 2025 margins were 58.6%, 15.9% and 15.5%, but the latest quarter is filed on a group basis while the prior quarter is on a company basis, so these are not like-for-like year-on-year changes.
On comparable group-basis March history, the latest operating margin ranked best of four quarters and net margin also ranked best of four. Gross margin ranked worst of four, showing that the operating improvement came despite weaker gross profitability. The June 2026 annual filing provides the latest full-year revenue and profit, but the supplied annual periods do not provide a valid like-for-like year-on-year comparison. Current shares outstanding are not reported, and no corporate action is recorded to explain per-share movements.
The latest quarter also carried a material below-line drag: finance costs, tax, associates and foreign-exchange items reduced operating profit before the final net result. This means the quality of earnings remains partly dependent on what happens below hospital operations, not only on the operating margin.
Risks
The main financial risk is that earnings are not converting fully into cash: cash conversion was 0.83x and free cash flow was LKR 35.7 million. The shortfall matters because a reported profit improvement is less useful when operating cash generation lags it.
Balance-sheet leverage is moderate, with total debt of LKR 152.6 million equal to gearing of 12.7% of owners' equity. Interest cover of 10.58x and a current ratio of 1.84x provide meaningful protection, but the company does not disclose the minority share of profit, leaving group earnings and the earnings attributable to listed shareholders difficult to distinguish.
The stock's high valuation is an additional company-specific risk: a P/E of 41.95 leaves limited room for operating results to disappoint. Healthcare-sector policy changes and import-cost conditions are relevant to the operating environment, but the supplied sector coverage does not establish a direct effect on Singhe Hospitals.
Outlook
As at 2026-08-08, the next scheduled filing is for the period ended 2026-06-30 and is marked due now, with the exchange-based expected window running from 2026-07-28 to 2026-10-26. That filing is the next concrete event capable of replacing the March-based analysis; the current data cannot establish whether the strong operating margin has continued on a comparable basis.
The wider healthcare backdrop includes phased tariff reform and lobbying for stronger pharmaceutical manufacturing capacity, while the broader market has seen lower interest rates but renewed fuel-price and inflation pressure. These are environmental factors rather than company news. With no direct coverage or corporate actions, the next filing remains the clearest evidence for judging whether operating improvement can justify the current valuation.